bioRxivPharmacology & Toxicology
A novel preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs
Abstract
In vitro secondary pharmacology assays are an important tool for predicting clinical adverse drug reactions (ADRs) of investigational drugs. We created the Secondary Pharmacology Database (SPD) by testing 1958 drugs using 200 assays to validate target-ADR associations. Compared to public and subscription resources, 95% of all and 36% of active (AC50 < 1 {micro}M) results were unique to SPD, with bias towards higher activity in public resources. Annotating drugs with free maximal plasma concentrations, we found 684 physiologically relevant novel off-target activities. Furthermore, 64% of putative ADRs linked to target activity in key literature reviews were not statistically significant in SPD. Systematic analysis of all target-ADR pairs identified several novel associations confirmed by publications. Finally, candidate mechanisms for known ADRs are proposed based on SPD off-target activities. Taken together, we present a unique freely-available resource for benchmarking ADR predictions, explaining novel phenotypic activity and investigating clinical properties of marketed drugs.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and post-marketing reports
I. A. Smit, A. M. Afzal, … A. Bender·bioRxiv·Jun 12, 2020
- Machine learning guided association of adverse drug reactions with in vitro target-based pharmacology
R. Ietswaart, S. Arat, … L. Urban·bioRxiv·Mar 12, 2020
- Quantifying the severity of adverse drug reactions using social media
Adam Lavertu, Tymor Hamamsy, Russ Biagio Altman·bioRxiv·Feb 2, 2021
- Predicting serious rare adverse reactions of novel chemicals
A. Poleksic, L. Xie·BioinformaticsPeer-reviewed·Mar 29, 2018
- Computational Drug Recommendation Approaches toward Safe Polypharmacy
Wen-Hao Chiang, Xia Ning·bioRxiv·Mar 24, 2019
- The Importance of Reverse Translation for Preclinical Off-Target Mitigation: Quantification and Mitigation of Biases in the FDA Adverse Event Reporting System
M. Maciejewski, E. Lounkine, … L. Urban·bioRxiv·Aug 14, 2016